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Radiation sensitization and chemopotentiation:
RSU 1069, a compound more efficient than misonidazole
in vitro and in vivo
G.E. Adams, I. Ahmed, P.W. Sheldon & I.J. Stratford
Physics Department, Institute ofCancer Research, Sutton, Surrey, SM2 5PX, UK.
Summary Electron affinity as measured by the one-electron reduction potential, E7,, is the major factor
influencing radiosensitizing efficiency in vitro. RSU 1069 has an electron affinity (E1 -398 mV) similar to
misonidazole; however, the ability of this compound to sensitize hypoxic cells is considerably greater thdn
that of misonidazole, e.g. 0.2mM RSU 1069 gives an enhancement ratio of 2.2 compared to 1.5 for the same
concentration of misonidazole. Radiosensitization studies with the MT tumour in vivo also showed RSU 1069
to be a more efficient sensitizer than misonidazole. An administered dose of only 0.08 mg g1 RSU 1069
yielded an enhancement of 1.8 to 1.9 using tumour cell survival and tumour cure as end-points.
The ability of RSU 1069 to potentiate the cytotoxic action of melphalan towards the MT tumour was also
examined. RSU 1069 (0.08 mgg-1) given to mice 1 h before melphalan resulted in an enhancement of 3.0. In
contrast, previous studies had shown with a series of nitroimidazoles including misonidazole that Ro 03-8799
was the most effective potentiating agent, but this only gave an enhancement of 2.3 at a 10-fold higher dose
than RSU 1069.
RSU 1069 is a compound of substantial promise both as a radiosensitizer and chemopotentiating agent and
warrants further investigation.
Many electron affinic compounds can act as
hypoxic cell radiosensitizers in experimental
systems. One, misonidazole (MISO), has undergone
considerable clinical evaluation but it is now clear
that the neurotoxic properties of this drug will
seriously limit its application. This is because the
maximum clinical doses that can be achieved fall
well short of those required for maximum
sensitizing effectiveness.
In vitro studies have shown that electron affinity
is generally the predominant factor which
determined both the cytotoxic and radiation sensi-
tizing efficiencies of hypoxia-mediated drugs
(Adams et al., 1979a, b, 1980a, b). However, there
are some exceptions; in particular a number of
compounds which show sensitizing efficiency much
greater than would be predicted from their electron
affinities. One such compound is the aziridinyl
dinitrobenzene, CB 1954, synthesized originally as a
cytotoxic agent (Cobb et al., 1969) and shown to
have both alkylating and anti-metabolite properties
(Connors & Malzack, 1971; Connors et al., 1972).
CB 1954 has an electron affinity similar to that of
MISO but its ability to sensitize hypoxic cells to
radiation is greater than that of MISO both in vitro
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and in vivo (Chapman et al., 1979; Stratford et al.,
1981; Stratford, 1982).
The compound 2-phenyl-4(5)-amino-5(4)-
carboxamide (phenyl AIC) is known to protect
against the cytotoxic effects of CB 1954 (Hickman
& Melzack, 1975). It has been shown that this
compound, when present during irradiation, also
reduces the efficiency of CB 1954 as a radiosensi-
tizer to the level which would be predicted from its
electron affinity (Stratford et al., 1981). It was
proposed, therefore, that the additional sensi-
tization normally seen with CB 1954 might be
associated with its cytotoxic activity.
We have subsequently included an aziridine
group in a 2-nitroimidazole. The compound
synthesized is RSU 1069 (NSC 347503, 1(2-nitro-1-
imidazolyl)-3-aziridino-2-propanol) and its structure
is given in figure 2. This agent shows considerably
greater activity than MISO both in vitro and in
vivo. This paper describes studies on radiosensi-
tization by RSU 1069 and on its ability to act as a
powerful potentiator of the anti-tumour action of
melphalan.
Materials and methods
Compounds
The compound RSU 1069 was synthesized from
azomycin in a similar manner to that described
for other (2-nitro-1-imidazolyl)propanolamines
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(Smithen et al., 1980) see Appendix. MISO and Ro
03-8799 were supplied by Dr C. Smithen, Roche
Products Ltd., Welwyn Garden City, Hertfordshire,
U.K. Melphalan (L-Pam, L-phenylalanine mustard)
was obtained from Burroughs Wellcome,
Beckenham, Kent, U.K.
Chemicalproperties
One-electron reduction potential, E', and the
octanol:water partition coefficients, P, were
measured as described previously (Adams et al.,
1976). The pKa of RSU 1069 was measured in
aqueous media at room temperature using standard
spectrophotometric methods.
Biological studies
Sensitizing efficiencies in vitro were obtained from
changes in slopes of the linear portions of the
radiation survival curves for hypoxic Chinese
hamster V79 cells irradiated in the presence of
various concentrations of RSU 1069.
Radiosensitization in vivo was measured using the
anaplastic MT tumour implanted s.c. over the
sacral region of the backs of female WHT/Cbi
mice. When the tumours reached 5-6mm in
diameter, the unanaesthetised mice were dosed i.p.
with RSU 1069 in saline, and locally irradiated with
230kV X-rays (Sheldon & Hill, 1977a). Tumour
response was determined either by an in vitro soft
agar clonogenic assay (Sheldon et al., 1982) or by
the probability of local tumour control at 80 days
(Sheldon & Hill, 1977b). The soft agar clonogenic
assay was also used in the chemopotentiation
studies, where male mice bearing the MT tumour
were treated i.p. with 5mgkg-1 melphalan. The in
vitro assay for tumour response was always carried
out 18h after radiation and/or drug treatment.
Results
Radiosensitization in vitro
Enhancement ratios were determined for radiation
sensitization of hypoxic Chinese hamster cells in
vitro by RSU 1069 using previously described
protocols (Adams et al., 1976, 1979a, 1980a). At
the maximum concentration tested, RSU 1069
reduced plating efficiency of unirradiated cells by
no more than 20% after a 2h contact time in
hypoxia at room temperature. Full hypoxic survival
curves were obtained for a range of concentrations
of RSU 1069. Some examples are shown in Figure
1. At these concentrations RSU 1069 greatly
increases the radiation response of hypoxic cells. In
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Figure 1 Survival curves for irradiated V79-379A
cells. Sensitization by RSU 1069. Solid symbols: air;
(0) control; (A) 0.15mmoldm3. Open symbols:
nitrogen; (0) control; (El) 0.1 mmoldm-3; ()
0.2mmoldm 3.
contrast, cells irradiated in air are not sensitized by
this compound. Enhancement ratios for some
concentrations were obtained from a single survival
point (usually between 2 x 10-2 and 10-1) obtained
by appropriate choice of radiation dose and by
assuming an unchanged extrapolation number.
Figure 2 shows the concentration dependence of the
enhancement ratios for RSU 1069. The ratios for
hypoxic cells irradiated in the presence of MISO
(dashed line in Figure 2) were similar to those
reported previously for this cell line (Adams et al.,
1976). Clearly RSU 1069 is a more efficient sensi-
tizer than MISO, i.e. a lower concentration is
required for any given value of ER. A comparison
of the values of ER obtained at a concentration of
0.2mM shows 2.2 for RSU 1069 and 1.5 for MISO;
a concentration of 2mM MISO is required to give
an ER of 2.2.
Table I shows some physical chemical data for
RSU 1069, MISO and some other compounds
under consideration at the present time as sensi-
tizers for clinical use. Also included in the table are
values of sensitization efficiency (C1.6), the concen-
tration required to give an ER of 1.6. All
compounds, with the exception of Ro 03-8799, have
similar electron affinities as measured by their one-
electron reduction potentials, E'. The E' for Ro 03-
8799 is somewhat higher and this is the. only
compound which in vitro shows sensitizing
efficiency close to that for RSU 1069.
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Hypoxic cell radiosensitization by RSU 1069
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Figure 2 Dependence of enhancement ratio for irradiated hypoxic V79-379A cells in the presence of various
concentrations of RSU 1069.
Table I Chemical and sensitizing efficiency data for compounds of
interest as potential hypoxic cell radiosensitizers for clinical use
Compound El/mV pd pKa Cl.6/mol.dm3
RSU 1069
(NSC 347503) -398 0.22 6.0 7.5 x 10-
MISO -389a 0.41k - 3.0x 10'4
Desmethylmisonidazole -389a 0.1' - 1.0x 10-3a
Ro 03-8799 -346b 8.5b 8.71 1.0 x 10
SR 2508 -388 0.046c - 3.0x 104
aAdams et al., 1976.
bSmithen et al., 1980.
CBrown & Workman 1980.
dp values for RSU 1069 and Ro 03-8799 were determined for the
unprotonated bases (i.e. pH>11.0).
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In vivo studies
Toxicity The LD50/7 for RSU 1069 administered
i.p. in saline to female WHT/Cbi mice is
0.l5mgg-'. At the LD50 dose, death occurred 4 to
6 days after treatment. In contrast, for compounds
such as MISO, that cause neurological damage,
death occurred within a day of dosing. This
probably indicates that the dose limiting tissue for
RSU 1069 lethality is not the same as that for
misonidazole.
Radiosensitization It is known that, due to
pharmacokinetic considerations, the time at which a
sensitizer is administered to tumour-bearing mice
prior to irradiation can greatly influence the
observed radiation response (Sheldon & Hill, 1977b;
McNally et al., 1978; Brown & Yu, 1980). There-
fore in initial experiments RSU 1069 was given i.p.
to tumour-bearing mice at various times before an
X-ray dose of 17Gy. The response of the MT
tumour to radiation +0.08mgg-1 RSU 1069
assessed by a clonogenic assay technique is shown
in Figure 3. Irradiation with a dose of 17Gy alone
only reduces tumour cell survival to 2 x 10-2. This
is in line with previous data (Stephens et al., 1980)
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Figure 3 Radiosensitization of the MT tumour in
WHT mice by RSU 1069. Effect of time between drug
administration and irradiation. Each point is derived
from 2 to 4 pooled tumours.
indicating that this tumour contains radiation-
resistant hypoxic cells. The decrease in cell survival
due to sensitization is dependent upon the interval
between drug administration and irradiation.
Maximum sensitization appears to occur when the
drug is given no earlier than 90min before
commencement of irradiation. For this time range
survival is decreased to around 3 x 10-4. When
RSU 1069 is given without irradiation, tumour cell
survival is reduced to 0.5. Taking this into account,
the maximum sensitization for this drug dose
corresponds to an enhancement ratio of 1.8. This
level of radiosensitization with MISO, in this
tumour system, requires at least a 15-fold higher
dose (Adams et al., 1984).
The sensitization efficiency of RSU 1069 was also
measured in vivo by the TCD50 method. A single
dose of 0.08mgg-1 was administered 90min before
the mice were given a range of doses of X-
irradiation in order to assess the probability of
local control of the MT tumour at 80 days. Data
are shown in Figure 4. In the absence of drug,
68Gy were required to achieve a 50% probability
of tumour control (TCD50). In the drug-tested
mice, the value of the TCD50 was reduced to 35Gy.
This corresponds to an enhancement ratio of 1.9,
and is consistent with the ER obtained from the
clonogenic assay.
Chemopotentiation We have .recently reported
chemopotentiation by misonidazole and a variety of
other nitroimidazoles of melphalan damage in the
30 50 70
X-ray dose 4Gy)
Figure 4 Probability of local control of the MT
tumour in WHT mice by radiation alone (X) or by
radiation plus 0.08mgg-I RSU 1069 given i.p. to mice
90min prior to X-rays (0). The standard errors on
the values of TCD50 are illustrated by the horizontal
bars. Eight mice were treated per point.
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MT tumour implanted intramuscularly (Sheldon et
al., 1982). This study showed that the compound
Ro 03-8799 produced the greatest potentiation. We
have compared the chemopotentiating properties of
RSU 1069 with Ro 03-8799 using the clonogenic
assay endpoint for subcutaneous tumours. Figure 5
shows the tumour cell response when the nitroimi-
dazoles were given to mice before or after
5mgkg- melphalan. Melphalan alone reduces
survival to 5 x 10-2 and the nitroimidazoles alone
reduce survival by no more than 50%. However,
the combination of the nitroimidazole with
melphalan can cause a large increase in cell killing.
The amount of potentiation is dependent upon the
timing and sequencing of the drug combination.
For Ro 03-8799 the optimum time is 30min. Before
melphalan, whereas for RSU 1069 it is 60min. A
dose of 0.72mgg-1 Ro 03-8799 with melphalan
produced a maximum reduction in cell survival of
10-3, whereas a 10-fold lower dose of RSU 1069
caused a further 10-fold decrease in cell survival.
These survival levels correspond to enhancement
ratios of 2.3 for Ro 03-8799 and 3.0 for RSU 1069.
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Figure 5 Potentiation of the cytotoxic effect of
melphalan towards the MT tumour in WHT mice. The
effects of Ro 03-8799 (X) or RSU 1069 (0) given at
various times before or after 0.5 ,ug g-' melphalan.
Each point is derived from 2 to 4 pooled tumours.
Discussion
Some compounds (Desmethylmisonidazole, SR
2508 and Ro 03-8799) have been or are being
considered as successors to misonidazole for clinical
use. Desmethylmisonidazole and SR 2508 have
similar sensitizing efficiencies to MISO both in vitro
and in vivo. They were chosen on the basis of
pharmacokinetic considerations suggesting the
drugs would be less neurotoxic (Dische et al., 1980;
Brown et al., 1981). Ro 03-8799 showed greater
sensitizing efficiency than MISO in vitro, but this
was not reflected in vivo, where levels of sensi-
tization were obtained which were no greater than
would be expected from a similar administered dose
of MISO (Williams et al., 1982). However, the
neurotoxicity of Ro 03-8799 was lower than MISO
in baboons, (Eichler & Jackson personal communi-
cation, in Saunders et al., 1982).
The compound RSU 1069 shows substantially
greater radiosensitizing efficiency than MISO both
in vitro and in vivo. This is the first nitroimidazole
shown to be substantially more efficient than MISO
in vivo. It warrants further evaluation in other
tumour systems using both single and multi-fraction
radiation regimes. It should be pointed out, that
RSU 1069 is more toxic than MISO as measured
by acute LD50 values in WHT/Cbi female mice
where the respective LD50's are 0.15mgg-1 and
1.8mgg-1. However, it would be premature at this
stage to make any conclusions regarding relative
therapeutic ratios without more detailed toxi-
cological evaluation.
There is currently considerable interest in the use
of MISO and other nitroimidazoles as potentiators
of alkylating agents in vivo (Rose et al., 1980;
Clement et al., 1980 Tannock, 1980a, b; Law et al.,
1981; Martin et al., 1981; Siemann, 1981; Mulcahy
et al., 1981; Stephens et al., 1981; Twentyman,
1981). Most of these combination studies have been
concerned with MISO. Recently it has been shown
that other nitro compounds can show potentiating
activity considerably greater than MISO (Workman
& Twentyman, 1982; Sheldon et al., 1982). In one
of these studies (Sheldon et al., 1982) Ro 03-8799
was found to be the most effective potentiator of
melphalan damage in the MT tumour, when
compared with a range of other nitroimidazoles
including MISO. RSU 1069 shows even greater
activity than Ro 03-8799.
If there were to be a wide role for hypoxic cell
sensitizers in radiotherapy, agents more effective
than MISO are required. There may also be a
clinical use for nitroimidazoles as chemopoten-
tiators. On the basis of the results reported here,
the compound RSU 1069 merits further
investigation576 G.E. ADAMS et al.
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Appendix
RSU 1069 gave satisfactory elemental and mass
spectural analyses. 1H.n.m.r. spectra were recorded
in CDC13 relative to 2,2-dimethyl-2-silopentane-5-
sulphonate as internal standard. Spin multiplicities
are indicated by the symbols s(singlet), m
(multiplet). Infrared spectra were recorded in nujol.
1-(2,3-epoxypropyl)-2-nitroimidazole (RSU 1062)
was prepared using the method described by
Beaman et al. (1967). RSU 1062 was mixed with a
twice molar excess of aziridine in methanol and
heated under reflux for one hour. The solvent was
removed under reduced pressure and the residue
recrystallised from ethanol to give RSU 1069, mp
119-121°C, as a pale yellow crystalline solid (yield
56%). I.R.v(cm-'): 3160, 3120, 3080, 1530, 1500,
1483, 1290, 1262, 1157, 1140, 1007, 920, 887, 848,
836, 787, 775, 650 and 630. 'H n.m.r. 5(p.p.m.): 7.35
(d,l,imid.H), 7.08 (d,l,imid.H), 4.15-5.01 (m,4,imid-
CH2-CHOH-, peak at 4.51 exchanging with D20),
2.32 (m,2,CH2-aziridine), 1.67 (m,2, aziridine) and
1.21 (m,2,aziridine).
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